APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Novel Drug Delivery Systems

Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.

Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.

Selected research

Market Outlook & Growth Opportunities

Global Novel Drug Delivery Systems Market Outlook and Growth Opportunities 2026

Report ID 173894990426 December 2025213 pages

Choose your research edition.

Industry ResearchNovel Drug Delivery Systems Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Novel Drug Delivery Systems Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Novel Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Novel Drug Delivery Systems Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Novel Drug Delivery Systems Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.

Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.

Global Novel Drug Delivery Systems key players include Amgen, Teva, Roche, UCB (Union Chimique Belge), etc. Global top four manufacturers hold a share over 40%.

Read the full market overview

North America is the largest market, with a share about 50%, followed by Asia-Pacific and Europe, both have a share over 40 percent.

In terms of product, PEGylated Proteins & Polypeptides is the largest segment, with a share about 40%. And in terms of application, the largest application is Hospitals & Clinic, followed by Cancer Treatment Centers, etc.

This report provides an overview of the global Novel Drug Delivery Systems market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Novel Drug Delivery Systems and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Novel Drug Delivery Systems revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Novel Drug Delivery Systems market.

Novel Drug Delivery Systems Segment by Company

Amgen

Teva

Roche

UCB (Union Chimique Belge)

Celgene

Merck

Gilead Sciences

Sanofi

Pfizer

Takeda

Bausch&Lomb

Samyang Biopharmaceuticals

Johnson & Johnson

TOLMAR

Astellas

AMAG Pharmaceuticals

AbbVie

Dr Reddy

AstraZeneca

Aspen

Acrotech Biopharma

TWi Pharmaceuticals

Novel Drug Delivery Systems Segment by Type

Liposomes

PEGylated Proteins & Polypeptides

Polymer Nanoparticle

Protein–drug Conjugates

Others

Novel Drug Delivery Systems Segment by Application

Hospitals & Clinic

Cancer Treatment Centers

Others

Novel Drug Delivery Systems Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Novel Drug Delivery Systems status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Novel Drug Delivery Systems key companies, revenue, market share, and recent developments.

3. To split the Novel Drug Delivery Systems breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Novel Drug Delivery Systems market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Novel Drug Delivery Systems significant trends, drivers, influence factors in global and regions.

6. To analyze Novel Drug Delivery Systems competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Novel Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Drug Delivery Systems.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Novel Drug Delivery Systems industry.

Chapter 3: Detailed analysis of Novel Drug Delivery Systems company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Novel Drug Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Novel Drug Delivery Systems in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Novel Drug Delivery Systems Industry Trends Table 2. Novel Drug Delivery Systems Industry Drivers Table 3. Novel Drug Delivery Systems Industry Opportunities and Challenges Table 4. Novel Drug Delivery Systems Industry Restraints Table 5. Global Novel Drug Delivery Systems Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Novel Drug Delivery Systems Revenue Share by Company (2021-2026) Table 7. Global Novel Drug Delivery Systems Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Novel Drug Delivery Systems Key Company Manufacturing Base & Headquarters Table 9. Global Novel Drug Delivery Systems Company, Product Type & Application Table 10. Global Novel Drug Delivery Systems Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Novel Drug Delivery Systems by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Liposomes Table 15. Significant Companies of PEGylated Proteins & Polypeptides Table 16. Significant Companies of Polymer Nanoparticle Table 17. Significant Companies of Protein–drug Conjugates Table 18. Significant Companies of Others Table 19. Global Novel Drug Delivery Systems Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Novel Drug Delivery Systems Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Novel Drug Delivery Systems Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Novel Drug Delivery Systems Sales Value Share by Type (2021-2026) Table 23. Global Novel Drug Delivery Systems Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals & Clinic Table 25. Significant Companies of Cancer Treatment Centers Table 26. Significant Companies of Others Table 27. Global Novel Drug Delivery Systems Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Novel Drug Delivery Systems Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Novel Drug Delivery Systems Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Novel Drug Delivery Systems Sales Value Share by Application (2021-2026) Table 31. Global Novel Drug Delivery Systems Sales Value Share by Application (2027-2032) Table 32. Global Novel Drug Delivery Systems Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Novel Drug Delivery Systems Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Novel Drug Delivery Systems Sales Value Share by Region (2021-2026) Table 35. Global Novel Drug Delivery Systems Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Novel Drug Delivery Systems Sales Value Share by Region (2027-2032) Table 37. Global Novel Drug Delivery Systems Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Novel Drug Delivery Systems Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Novel Drug Delivery Systems Sales Value Market Share by Country (2021-2026) Table 40. Global Novel Drug Delivery Systems Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Novel Drug Delivery Systems Sales Value Market Share by Country (2027-2032) Table 42. Amgen Company Information Table 43. Amgen Business Overview Table 44. Amgen Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Amgen Novel Drug Delivery Systems Product Portfolio Table 46. Amgen Recent Development Table 47. Teva Company Information Table 48. Teva Business Overview Table 49. Teva Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Teva Novel Drug Delivery Systems Product Portfolio Table 51. Teva Recent Development Table 52. Roche Company Information Table 53. Roche Business Overview Table 54. Roche Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Roche Novel Drug Delivery Systems Product Portfolio Table 56. Roche Recent Development Table 57. UCB (Union Chimique Belge) Company Information Table 58. UCB (Union Chimique Belge) Business Overview Table 59. UCB (Union Chimique Belge) Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. UCB (Union Chimique Belge) Novel Drug Delivery Systems Product Portfolio Table 61. UCB (Union Chimique Belge) Recent Development Table 62. Celgene Company Information Table 63. Celgene Business Overview Table 64. Celgene Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Celgene Novel Drug Delivery Systems Product Portfolio Table 66. Celgene Recent Development Table 67. Merck Company Information Table 68. Merck Business Overview Table 69. Merck Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Merck Novel Drug Delivery Systems Product Portfolio Table 71. Merck Recent Development Table 72. Gilead Sciences Company Information Table 73. Gilead Sciences Business Overview Table 74. Gilead Sciences Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Gilead Sciences Novel Drug Delivery Systems Product Portfolio Table 76. Gilead Sciences Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Sanofi Novel Drug Delivery Systems Product Portfolio Table 81. Sanofi Recent Development Table 82. Pfizer Company Information Table 83. Pfizer Business Overview Table 84. Pfizer Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Pfizer Novel Drug Delivery Systems Product Portfolio Table 86. Pfizer Recent Development Table 87. Takeda Company Information Table 88. Takeda Business Overview Table 89. Takeda Novel Drug Delivery Systems Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Takeda Novel Drug Delivery Systems Product Portfolio Table 91. Takeda Recent Development Table 92. Bausch&Lomb Company Information Table 93. Bausch&Lomb Business Overview Table 94. Bausch&Lomb Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Bausch&Lomb Novel Drug Delivery Systems Product Portfolio Table 96. Bausch&Lomb Recent Development Table 97. Samyang Biopharmaceuticals Company Information Table 98. Samyang Biopharmaceuticals Business Overview Table 99. Samyang Biopharmaceuticals Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Samyang Biopharmaceuticals Novel Drug Delivery Systems Product Portfolio Table 101. Samyang Biopharmaceuticals Recent Development Table 102. Johnson & Johnson Company Information Table 103. Johnson & Johnson Business Overview Table 104. Johnson & Johnson Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. Johnson & Johnson Novel Drug Delivery Systems Product Portfolio Table 106. Johnson & Johnson Recent Development Table 107. TOLMAR Company Information Table 108. TOLMAR Business Overview Table 109. TOLMAR Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 110. TOLMAR Novel Drug Delivery Systems Product Portfolio Table 111. TOLMAR Recent Development Table 112. Astellas Company Information Table 113. Astellas Business Overview Table 114. Astellas Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 115. Astellas Novel Drug Delivery Systems Product Portfolio Table 116. Astellas Recent Development Table 117. AMAG Pharmaceuticals Company Information Table 118. AMAG Pharmaceuticals Business Overview Table 119. AMAG Pharmaceuticals Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 120. AMAG Pharmaceuticals Novel Drug Delivery Systems Product Portfolio Table 121. AMAG Pharmaceuticals Recent Development Table 122. AbbVie Company Information Table 123. AbbVie Business Overview Table 124. AbbVie Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 125. AbbVie Novel Drug Delivery Systems Product Portfolio Table 126. AbbVie Recent Development Table 127. Dr Reddy Company Information Table 128. Dr Reddy Business Overview Table 129. Dr Reddy Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 130. Dr Reddy Novel Drug Delivery Systems Product Portfolio Table 131. Dr Reddy Recent Development Table 132. AstraZeneca Company Information Table 133. AstraZeneca Business Overview Table 134. AstraZeneca Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 135. AstraZeneca Novel Drug Delivery Systems Product Portfolio Table 136. AstraZeneca Recent Development Table 137. Aspen Company Information Table 138. Aspen Business Overview Table 139. Aspen Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 140. Aspen Novel Drug Delivery Systems Product Portfolio Table 141. Aspen Recent Development Table 142. Acrotech Biopharma Company Information Table 143. Acrotech Biopharma Business Overview Table 144. Acrotech Biopharma Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 145. Acrotech Biopharma Novel Drug Delivery Systems Product Portfolio Table 146. Acrotech Biopharma Recent Development Table 147. TWi Pharmaceuticals Company Information Table 148. TWi Pharmaceuticals Business Overview Table 149. TWi Pharmaceuticals Novel Drug Delivery Systems Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 150. TWi Pharmaceuticals Novel Drug Delivery Systems Product Portfolio Table 151. TWi Pharmaceuticals Recent Development Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Novel Drug Delivery Systems Product Image Figure 2. Global Novel Drug Delivery Systems Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Novel Drug Delivery Systems Market Size (2021-2032) & (US$ Million) Figure 4. Global Novel Drug Delivery Systems Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Liposomes Image Figure 8. PEGylated Proteins & Polypeptides Image Figure 9. Polymer Nanoparticle Image Figure 10. Protein–drug Conjugates Image Figure 11. Others Image Figure 12. Global Novel Drug Delivery Systems Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Novel Drug Delivery Systems Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Novel Drug Delivery Systems Sales Value Share by Type (2021-2032) Figure 15. Hospitals & Clinic Image Figure 16. Cancer Treatment Centers Image Figure 17. Others Image Figure 18. Global Novel Drug Delivery Systems Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Novel Drug Delivery Systems Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Novel Drug Delivery Systems Sales Value Share by Application (2021-2032) Figure 21. Global Novel Drug Delivery Systems Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Novel Drug Delivery Systems Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Novel Drug Delivery Systems Sales Value (2021-2032) & (US$ Million) Figure 24. North America Novel Drug Delivery Systems Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Novel Drug Delivery Systems Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Novel Drug Delivery Systems Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Novel Drug Delivery Systems Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Novel Drug Delivery Systems Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Novel Drug Delivery Systems Sales Value (2021-2032) & (US$ Million) Figure 30. South America Novel Drug Delivery Systems Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Novel Drug Delivery Systems Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Novel Drug Delivery Systems Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Liposomes
  • PEGylated Proteins & Polypeptides
  • Polymer Nanoparticle
  • Protein–drug Conjugates
  • Others
Applications
  • Hospitals & Clinic
  • Cancer Treatment Centers
  • Others
Companies covered
  • Amgen
  • Teva
  • Roche
  • UCB (Union Chimique Belge)
  • Celgene
  • Merck
  • Gilead Sciences
  • Sanofi
  • Pfizer
  • Takeda
  • Bausch&Lomb
  • Samyang Biopharmaceuticals
  • Johnson & Johnson
  • TOLMAR
  • Astellas
  • AMAG Pharmaceuticals
  • AbbVie
  • Dr Reddy
  • AstraZeneca
  • Aspen
  • Acrotech Biopharma
  • TWi Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Novel Drug Delivery Systems Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Novel Drug Delivery Systems Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Novel Drug Delivery Systems Market Dynamics
  1. 2.1 Novel Drug Delivery Systems Industry Trends
  2. 2.2 Novel Drug Delivery Systems Industry Drivers
  3. 2.3 Novel Drug Delivery Systems Industry Opportunities and Challenges
  4. 2.4 Novel Drug Delivery Systems Industry Restraints
3 Novel Drug Delivery Systems Market by Company
  1. 3.1 Global Novel Drug Delivery Systems Company Revenue Ranking in 2025
  2. 3.2 Global Novel Drug Delivery Systems Revenue by Company (2021-2026)
  3. 3.3 Global Novel Drug Delivery Systems Company Ranking (2024-2026)
  4. 3.4 Global Novel Drug Delivery Systems Company Manufacturing Base and Headquarters
  5. 3.5 Global Novel Drug Delivery Systems Company Product Type and Application
  6. 3.6 Global Novel Drug Delivery Systems Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Novel Drug Delivery Systems Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Novel Drug Delivery Systems Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Novel Drug Delivery Systems Market by Type
  1. 4.1 Novel Drug Delivery Systems Type Introduction
  2. 4.1.1 Liposomes
  3. 4.1.2 PEGylated Proteins & Polypeptides
  4. 4.1.3 Polymer Nanoparticle
  5. 4.1.4 Protein–drug Conjugates
  6. 4.1.5 Others
  7. 4.2 Global Novel Drug Delivery Systems Sales Value by Type
  8. 4.2.1 Global Novel Drug Delivery Systems Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Novel Drug Delivery Systems Sales Value by Type (2021-2032)
  10. 4.2.3 Global Novel Drug Delivery Systems Sales Value Share by Type (2021-2032)
5 Novel Drug Delivery Systems Market by Application
  1. 5.1 Novel Drug Delivery Systems Application Introduction
  2. 5.1.1 Hospitals & Clinic
  3. 5.1.2 Cancer Treatment Centers
  4. 5.1.3 Others
  5. 5.2 Global Novel Drug Delivery Systems Sales Value by Application
  6. 5.2.1 Global Novel Drug Delivery Systems Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Novel Drug Delivery Systems Sales Value by Application (2021-2032)
  8. 5.2.3 Global Novel Drug Delivery Systems Sales Value Share by Application (2021-2032)
6 Novel Drug Delivery Systems Regional Value Analysis
  1. 6.1 Global Novel Drug Delivery Systems Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Novel Drug Delivery Systems Sales Value by Region (2021-2032)
  3. 6.2.1 Global Novel Drug Delivery Systems Sales Value by Region: 2021-2026
  4. 6.2.2 Global Novel Drug Delivery Systems Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Novel Drug Delivery Systems Sales Value (2021-2032)
  7. 6.3.2 North America Novel Drug Delivery Systems Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Novel Drug Delivery Systems Sales Value (2021-2032)
  10. 6.4.2 Europe Novel Drug Delivery Systems Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Novel Drug Delivery Systems Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Novel Drug Delivery Systems Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Novel Drug Delivery Systems Sales Value (2021-2032)
  16. 6.6.2 South America Novel Drug Delivery Systems Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Novel Drug Delivery Systems Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Novel Drug Delivery Systems Sales Value Share by Country, 2025 VS 2032
7 Novel Drug Delivery Systems Country-level Value Analysis
  1. 7.1 Global Novel Drug Delivery Systems Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Novel Drug Delivery Systems Sales Value by Country (2021-2032)
  3. 7.2.1 Global Novel Drug Delivery Systems Sales Value by Country (2021-2026)
  4. 7.2.2 Global Novel Drug Delivery Systems Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Novel Drug Delivery Systems Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Novel Drug Delivery Systems Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Novel Drug Delivery Systems Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Novel Drug Delivery Systems Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Novel Drug Delivery Systems Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Novel Drug Delivery Systems Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 UCB (Union Chimique Belge)
  20. 8.4.1 UCB (Union Chimique Belge) Company Information
  21. 8.4.2 UCB (Union Chimique Belge) Business Overview
  22. 8.4.3 UCB (Union Chimique Belge) Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  23. 8.4.4 UCB (Union Chimique Belge) Novel Drug Delivery Systems Product Portfolio
  24. 8.4.5 UCB (Union Chimique Belge) Recent Developments
  25. 8.5 Celgene
  26. 8.5.1 Celgene Company Information
  27. 8.5.2 Celgene Business Overview
  28. 8.5.3 Celgene Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Celgene Novel Drug Delivery Systems Product Portfolio
  30. 8.5.5 Celgene Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Novel Drug Delivery Systems Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Gilead Sciences
  38. 8.7.1 Gilead Sciences Company Information
  39. 8.7.2 Gilead Sciences Business Overview
  40. 8.7.3 Gilead Sciences Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gilead Sciences Novel Drug Delivery Systems Product Portfolio
  42. 8.7.5 Gilead Sciences Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Novel Drug Delivery Systems Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Novel Drug Delivery Systems Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Takeda
  56. 8.10.1 Takeda Company Information
  57. 8.10.2 Takeda Business Overview
  58. 8.10.3 Takeda Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Takeda Novel Drug Delivery Systems Product Portfolio
  60. 8.10.5 Takeda Recent Developments
  61. 8.11 Bausch&Lomb
  62. 8.11.1 Bausch&Lomb Company Information
  63. 8.11.2 Bausch&Lomb Business Overview
  64. 8.11.3 Bausch&Lomb Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bausch&Lomb Novel Drug Delivery Systems Product Portfolio
  66. 8.11.5 Bausch&Lomb Recent Developments
  67. 8.12 Samyang Biopharmaceuticals
  68. 8.12.1 Samyang Biopharmaceuticals Company Information
  69. 8.12.2 Samyang Biopharmaceuticals Business Overview
  70. 8.12.3 Samyang Biopharmaceuticals Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Samyang Biopharmaceuticals Novel Drug Delivery Systems Product Portfolio
  72. 8.12.5 Samyang Biopharmaceuticals Recent Developments
  73. 8.13 Johnson & Johnson
  74. 8.13.1 Johnson & Johnson Company Information
  75. 8.13.2 Johnson & Johnson Business Overview
  76. 8.13.3 Johnson & Johnson Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Johnson & Johnson Novel Drug Delivery Systems Product Portfolio
  78. 8.13.5 Johnson & Johnson Recent Developments
  79. 8.14 TOLMAR
  80. 8.14.1 TOLMAR Company Information
  81. 8.14.2 TOLMAR Business Overview
  82. 8.14.3 TOLMAR Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  83. 8.14.4 TOLMAR Novel Drug Delivery Systems Product Portfolio
  84. 8.14.5 TOLMAR Recent Developments
  85. 8.15 Astellas
  86. 8.15.1 Astellas Company Information
  87. 8.15.2 Astellas Business Overview
  88. 8.15.3 Astellas Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Novel Drug Delivery Systems Product Portfolio
  90. 8.15.5 Astellas Recent Developments
  91. 8.16 AMAG Pharmaceuticals
  92. 8.16.1 AMAG Pharmaceuticals Company Information
  93. 8.16.2 AMAG Pharmaceuticals Business Overview
  94. 8.16.3 AMAG Pharmaceuticals Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AMAG Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
  96. 8.16.5 AMAG Pharmaceuticals Recent Developments
  97. 8.17 AbbVie
  98. 8.17.1 AbbVie Company Information
  99. 8.17.2 AbbVie Business Overview
  100. 8.17.3 AbbVie Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  101. 8.17.4 AbbVie Novel Drug Delivery Systems Product Portfolio
  102. 8.17.5 AbbVie Recent Developments
  103. 8.18 Dr Reddy
  104. 8.18.1 Dr Reddy Company Information
  105. 8.18.2 Dr Reddy Business Overview
  106. 8.18.3 Dr Reddy Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Dr Reddy Novel Drug Delivery Systems Product Portfolio
  108. 8.18.5 Dr Reddy Recent Developments
  109. 8.19 AstraZeneca
  110. 8.19.1 AstraZeneca Company Information
  111. 8.19.2 AstraZeneca Business Overview
  112. 8.19.3 AstraZeneca Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  113. 8.19.4 AstraZeneca Novel Drug Delivery Systems Product Portfolio
  114. 8.19.5 AstraZeneca Recent Developments
  115. 8.20 Aspen
  116. 8.20.1 Aspen Company Information
  117. 8.20.2 Aspen Business Overview
  118. 8.20.3 Aspen Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Aspen Novel Drug Delivery Systems Product Portfolio
  120. 8.20.5 Aspen Recent Developments
  121. 8.21 Acrotech Biopharma
  122. 8.21.1 Acrotech Biopharma Company Information
  123. 8.21.2 Acrotech Biopharma Business Overview
  124. 8.21.3 Acrotech Biopharma Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Acrotech Biopharma Novel Drug Delivery Systems Product Portfolio
  126. 8.21.5 Acrotech Biopharma Recent Developments
  127. 8.22 TWi Pharmaceuticals
  128. 8.22.1 TWi Pharmaceuticals Company Information
  129. 8.22.2 TWi Pharmaceuticals Business Overview
  130. 8.22.3 TWi Pharmaceuticals Novel Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  131. 8.22.4 TWi Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
  132. 8.22.5 TWi Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst